BioSpaceOriginal article
AstraZeneca pulls plug on late-stage lung cancer trial, extending losing streak
Phase 3negativevolrustomigNegative
AI Analysis
Summary
AstraZeneca discontinued a late-stage Phase 3 trial of volrustomig in lung cancer while continuing development in cervical cancer and mesothelioma indications.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Late-stage lung cancer trial discontinued
Importance:7/10
Sentiment:
-0.80
trial discontinuationPhase 3lung cancervolrustomigcervical cancermesothelioma
Related Companies
Read the original article
Published by BioSpace on August 17, 2026 12:11 PM